A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. The Swons Gynaecological Cancer Group.

Eighty-eight patients with stage IIB-III epithelial ovarian cancer were randomised to receive first line single agent cisplatin (100 mg/m2) monthly or carboplatin (400 mg/m2) monthly for up to 5 cycles. Crossover to the opposite analogue occurred with progression or lack of response. All patients were premedicated with i.

The clinical value of serum CA125 levels in ovarian cancer patients receiving platinum therapy.

Serum CA125 concentrations are elevated in 60% (49/86) of patients, with histologically proven residual adenocarcinoma of the ovary, before chemotherapy. The frequency of elevated levels correlates with stage of disease and tumour size but not histological tumour type. Serial antigen determinations in 44 patients receiving monthly i.

A controlled clinical trial in advanced ovarian cancer.

Thirty-eight patients with an advanced ovarian cancer (FIGO stage III and IV) were randomly allocated to treatment, either with melphalan (M) or a combination of adriamycin, 5-fluorouracil and cyclophosphamide (CAF) to determine the effect on survival. Actuarial survival of the two treatment groups was the same but the combination was more toxic.

Antenatal diagnosis of Duchenne muscular dystrophy.

As a means of assessing the value of fetal serum-creatine-kinase (S.C.K.